All NewsEducationTV
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Cava CEO: GLP-1 Drugs Fueling Demand for 'Big Kids' Market

Created at 12 Aug · 6:06 AM1 source↑ Market-relevant
IN SHORT

Cava CEO Brett Schulman noted an increase in adult customers, whom he calls 'big kids,' opting for kids' meal portions, attributing this trend to the use of GLP-1 weight-loss drugs. The casual dining chain's offerings align with the reduced portion sizes favored by these consumers.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Key Numbers

$8.25Cava kids' meal price
$12.95Cava full-sized bowl starting price
31.3%Second-quarter revenue increase
9%Second-quarter same-store sales increase
17New restaurants opened in the quarter

Who's Involved

Brett Schulman
CEO of Cava, who identified the 'big kids' market trend
Cava
Casual dining chain reporting strong earnings and observing consumer shifts
Cava CEO: GLP-1 Drugs Fueling Demand for 'Big Kids' Market

↳ Why This Matters

The growing influence of GLP-1 weight-loss drugs is reshaping consumer behavior and product demand across the food industry, impacting everything from restaurant portion sizes to packaged goods, and signaling a significant shift in the market for casual dining chains.

Key facts

  • Cava CEO Brett Schulman observed an increase in adult customers choosing kids' meal portions.
  • Schulman linked this trend to consumers using GLP-1 weight-loss drugs.
  • He stated Cava's Mediterranean-style food aligns with the dietary shifts associated with GLP-1 drugs.
  • Cava's second-quarter revenue rose 31.3% year-over-year.
  • Same-store sales increased by 9% compared to the previous year.

    • Cava CEO Brett Schulman has identified a growing trend of adult customers, whom he dubs 'big kids,' opting for kids' meal portions, a shift he attributes to the increasing use of GLP-1 weight-loss drugs. During a recent earnings call, Schulman explained that Cava's Mediterranean-style offerings, which emphasize protein, naturally align with the dietary preferences of individuals using these drugs.

    He noted that while some 'big kids' are choosing the kids' meal, which costs $8.25 and features smaller portions of grains and mains, the broader trend is more people shifting towards Cava's brand and its style of eating. Full-sized bowls at Cava start at $12.95.

    This observation from Cava is the latest indication of the 'Ozempification of American food,' a phenomenon where shrinking appetites lead consumers to favor smaller portions. Packaged food companies like General Mills and Conagra Brands have already responded by introducing smaller-portion products, some marketed as 'GLP-1 Friendly.'

    Cava's financial performance also showed strength, with the company reporting a 31.3% increase in revenue and a 9% rise in same-store sales for the second quarter compared to the previous year. The chain also expanded its footprint by opening 17 new restaurants during the quarter, signaling a comeback for fast-casual 'slop bowl' concepts.

    Frequently asked questions

    The 'big kids' market refers to adult customers, particularly those using GLP-1 weight-loss drugs, who are opting for smaller portion sizes, such as those found in kids' meals.

    GLP-1 drugs can reduce appetite and alter food preferences, leading users to consume smaller portions and seek out nutrient-dense, protein-rich foods.

    Cava reported a 31.3% increase in revenue and a 9% rise in same-store sales for its second quarter, along with opening 17 new restaurants.

    What Happens Next

    01Further observation of consumer behavior related to GLP-1 drug usage.
    02Potential for other restaurant chains to adapt portion sizes or offerings.

    Get the newsletter.

    Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

    Cadence

    How It Developed

    Cava CEO Brett Schulman identified a growing consumer base he terms 'big kids.'
    Schulman stated these 'big kids' are adults on GLP-1 drugs choosing smaller portions.
    He noted Cava's Mediterranean diet offerings align with GLP-1 consumers' preferences.
    Cava reported a 31.3% revenue increase and 9% same-store sales growth in the second quarter.
    The company opened 17 new restaurants during the quarter.

    Sources

    T1
    GLP-1 drugs are fueling the rise of the 'big kids' market, one mega restaurant chain saysBusiness Insider

    Related Stories

    Fast-food chains find discounts alone fail to attract diners
    11 Aug · 10:51 AM
    Taylor Farms lettuce recall: Taco Bell received less than 2.5% of contaminated product
    11 Aug · 6:06 PM
    Bridal brands prepare Swift-inspired designs amid legal risk concerns
    11 Aug · 10:17 AM
    Smithfield Foods Cuts Annual Forecasts Amid Consumer Spending Squeeze
    11 Aug · 9:48 AM
    Global drugmakers pledge $500B to expand US manufacturing and research
    11 Aug · 5:08 PM